Stockreport

Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates [Yahoo! Finance]

TENCENT HLDGS UNSP/ADR  (TCEHY) 
NASDAQ:AMEX Investor Relations: tencent.com/en-us/investor.html
PDF Enveda pipeline consists of multiple first-in-class and best-in-class programs across Immunology & Inflammation, Obesity, Fibrosis, and Neurosensory indications BOULD [Read more]